MetaVia's DA-1726 matches retatrutide weight loss in mouse study
MTVA•MetaVia said DA-1726 matched retatrutide’s weight loss with less appetite suppression in obese mice. Results also showed greater glucose lowering and increased levels of a liver hormone involved in metabolism; the company plans to begin a Phase 2 trial in MetALD and ALD in the second half of 2027.
1. Preclinical results
MetaVia reported preclinical results presented Nov. 14, 2026, at ObesityWeek, showing DA-1726 matched retatrutide’s weight loss with less appetite suppression in obese mice. The findings also showed greater glucose lowering and increased levels of a liver hormone involved in metabolism, and support plans to begin a Phase 2 trial in MetALD and ALD in the second half of 2027.




